# Immunomodulation by Mesenchymal Stem Cells A Potential Therapeutic Strategy for Type 1 Diabetes

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.2337/db08-0180</td>
</tr>
<tr>
<td>Citable link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:8438171">http://nrs.harvard.edu/urn-3:HUL.InstRepos:8438171</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>
Immunomodulation by Mesenchymal Stem Cells
A Potential Therapeutic Strategy for Type 1 Diabetes
Reza Abdi,1 Paolo Fiorina,1,2 Chaker N. Adra,1,3 Mark Atkinson,4 and Mohamed H. Sayegh1,3

Mesenchymal stem cells (MSCs) are pluripotent stromal cells that have the potential to give rise to cells of diverse lineages. Interestingly, MSCs can be found in virtually all postnatal tissues. The main criteria currently used to characterize and identify these cells are the capacity for self-renewal and differentiation into tissues of mesodermal origin, combined with a lack in expression of certain hematopoietic molecules. Because of their developmental plasticity, the notion of MSC-based therapeutic intervention has become an emerging strategy for the replacement of injured tissues. MSCs have also been noted to possess the ability to impart profound immunomodulatory effects in vivo. Indeed, some of the initial observations regarding MSC protection from tissue injury owe their potential for clinical use as a cell-based therapy for immune-mediated disorders and, in particular, type 1 diabetes. Diabetes 57:1759–1767, 2008

WHAT ARE MESENCHYMAL STEM CELLS?
Historical perspective, definitions, and tissue localization. More than a century ago, the presence of progenitor cells in bone marrow with the capability of differentiating to bone was identified (1,2). A series of landmark observations by Friedenstein and colleagues (3,4) led to identification of the clonogenic potential of fibroblast-like cells residing in bone marrow (1). By low-density culturing of bone marrow on plastic culture dishes, Friedenstein and colleagues were able to discard nonadherent hematopoietic stem cells and identify plastic-adherent cells or colony-forming unit fibroblasts, which were later introduced largely by Owen (5) as mesenchymal stromal cells. The term “mesenchymal stem cells” (MSC) appeared in the early 1980s (6) and was largely popularized by Caplan (7). Although studies highlighting the differentiation capabilities of MSC into various cell lineages including bone, cartilage, and adipose tissue have been repeatedly described over the past decade, some investigators argue that the “stemness” of MSCs is lacking, proposing instead to use the term “multipotent mesenchymal stromal cells” (8). While the acronym MSC has become the predominant term used within the literature, no matter what terminology one chooses to use, the field investigating these cells has grown rapidly because of the marked potential in terms of therapeutic exploitation.

As noted previously, MSCs are self-renewable multipotent progenitor cells that have the potential to differentiate into various lineages (9). Whereas bone marrow MSCs represent a rare population of cells that make up only 0.001 to 0.01% of total nucleated cells and are 10-fold less abundant than hematopoietic stem cells, they can be readily grown and expanded in culture (10). The frequency of MSCs in postnatal bone marrow has been reported to decline with increasing age (11). Much of our knowledge regarding MSCs has been generated from studies using bone marrow–derived MSCs. However, the source tissue for studies of MSCs has recently been expanded to cells deriving from virtually all tissues including muscle, adipose tissue, and umbilical cord blood (12). It is important to note that the origin of MSCs may determine their fate and functional characteristics (13). Furthermore, whereas the exact functions of MSCs within tissues remain largely unknown, they appear to exert different functions in specific tissues where they reside. For instance, in bone marrow, they are reported to represent the precursor cell for stromal tissues that support hematopoiesis (14). In other tissues, upon receiving appropriate biological signals during tissue injury or inflammation, they may differentiate into specialized cells and play a pivotal role in tissue repair and/or control of inflammation in situ.

MSC characteristics and methods for their isolation. From the outset, it is important to note that there is no universally agreed upon set or specific singular marker to identify these cells. As a result, a battery of negative and positive markers is generally used to phenotypically characterize these cells. MSCs generally lack specific cell surface markers of hematopoietic cells (CD14, CD34, CD11a/LFA-1, and CD45), erythrocytes (glycophorin A), and platelet and endothelial cell adhesion molecules (CD31). They express variable levels of CD105 (CD31), CD73 (SH3/4), CD44, stromal antigen 1, and a group of other adhesion molecules and receptors including CD166 (vascular cell adhesion molecule), CD54/CD102 (intracellular adhesion molecule), and CD49 (very late antigen) (15). Finally, their ability to differentiate into several mesenchymal lineages has also been used as an identity marker.
Immunomodulatory properties of MSCs in vitro. The functional activities of MSCs enriching MSCs (9). Identifications for some of the MSC markers for the purpose of excluding hematopoietic stem cells, or using positive selection for adherence of marrow-derived hematopoietic cells (16). Recovered from bone marrow) to the plastic substrate of a setting in which one uses “third party” MSCs. MSCs also significantly reduce the expression of certain activation markers (18); suppress proliferation of both CD4+ and CD8+ lymphocytes; and are able to abrogate the response of memory T-cells to their antigen (19).

The immunomodulatory ability of MSCs appears to take effect before the secretion of interleukin (IL)-2, since MSC-mediated anti-proliferative effects on mitogen-stimulated peripheral blood lymphocytes can be reversed (in part) by the addition of exogenous IL-2 (17). Additional studies have noted that supernatants of MSCs were unable to suppress proliferation (15). However, using a transwell culture system with a semipermeable membrane to separate MSC from leucocytes, one effort did note an inhibitory function in terms of suppression, findings that suggest the presence of soluble factors capable of suppression (20). Among the many candidates that could represent such a soluble factor, members of the transforming growth factor superfamily (transforming growth factor-β), hepatic growth factors, prostaglandin E2, and IL-10 secreted by MSCs have all been found to suppress T-cell-mediated antigen responses in vitro (9). Furthermore, Meisel et al. (21) reported induction indolamine 2,3-dioxygenase expression by MSC stimulated with interferon (IFN)-γ. Thus, MSC inhibition of T-cell proliferation could also be due to a depletion of tryptophan (i.e., indolamine 2,3-dioxygenase catalyzes the conversion of tryptophan to kynurenin) and subsequent inhibition of T-cell proliferation. Inducible nitric oxide synthase and heme oxygenase-1 expressed by MSCs have also been implicated for their immunosuppressive properties (22,23). It is likely that these mechanisms are not mutually exclusive and that the relative contribution of each mechanism to modulating immune responses varies in different experimental models. It is also interesting to hypothesize that immunomodulation of MSCs in different tissues may be mediated by different factors. One should note, however, that lack of standarization in isolation and culture conditions and strain-dependent variation has given rise to conflicting findings and interpretations (24).

**FUNCTIONAL ACTIVITIES OF MSCs**

**Immunomodulatory properties of MSCs in vitro.** The immunomodulatory properties of MSCs were initially reported in T-cell proliferation assays using one of a variety of stimuli including mitogens, CD3/CD28, and alloantigens; settings where the ability of MSCs to suppress T-cell proliferation can readily be determined (17,18). Such suppression occurs irrespective of donor source, including settings in which one uses “third party” MSCs. MSCs also significantly reduce the expression of certain activation markers including CD25, CD38, and CD69 on PHA-stimulated lymphocytes (18); suppress proliferation of both CD4+ and CD8+ lymphocytes; and are able to abrogate the response of memory T-cells to their antigen (19).

The immunomodulatory ability of MSCs appears to take effect before the secretion of interleukin (IL)-2, since MSC-mediated anti-proliferative effects on mitogen-stimulated peripheral blood lymphocytes can be reversed (in part) by the addition of exogenous IL-2 (17). Additional studies have noted that supernatants of MSCs were unable to suppress proliferation (15). However, using a transwell culture system with a semipermeable membrane to separate MSC from leucocytes, one effort did note an inhibitory function in terms of suppression, findings that suggest the presence of soluble factors capable of suppression (20). Among the many candidates that could represent such a soluble factor, members of the transforming growth factor superfamily (transforming growth factor-β), hepatic growth factors, prostaglandin E2, and IL-10 secreted by MSCs have all been found to suppress T-cell-mediated antigen responses in vitro (9). Furthermore, Meisel et al. (21) reported induction indolamine 2,3-dioxygenase expression by MSC stimulated with interferon (IFN)-γ. Thus, MSC inhibition of T-cell proliferation could also be due to a depletion of tryptophan (i.e., indolamine 2,3-dioxygenase catalyzes the conversion of tryptophan to kynurenin) and subsequent inhibition of T-cell proliferation. Inducible nitric oxide synthase and heme oxygenase-1 expressed by MSCs have also been implicated for their immunosuppressive properties (22,23). It is likely that these mechanisms are not mutually exclusive and that the relative contribution of each mechanism to modulating immune responses varies in different experimental models. It is also interesting to hypothesize that immunomodulation of MSCs in different tissues may be mediated by different factors. One should note, however, that lack of standardization in isolation and culture conditions and strain-dependent variation has given rise to conflicting findings and interpretations (24).

**TABLE 1**

<table>
<thead>
<tr>
<th>Markers used to characterize or extract human and murine MSCs</th>
<th>Human MSCs</th>
<th>Murine MSCs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FACS markers</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD10</td>
<td>–</td>
<td>+/–</td>
</tr>
<tr>
<td>CD11b</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>CD13</td>
<td>+</td>
<td>+/–</td>
</tr>
<tr>
<td>CD29</td>
<td>+/–</td>
<td>++</td>
</tr>
<tr>
<td>CD31</td>
<td>–/+</td>
<td>–</td>
</tr>
<tr>
<td>CD34</td>
<td>–</td>
<td>–/–</td>
</tr>
<tr>
<td>CD44</td>
<td>+</td>
<td>++</td>
</tr>
<tr>
<td>CD45</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>CD73</td>
<td>+</td>
<td>0</td>
</tr>
<tr>
<td>CD90</td>
<td>+</td>
<td>–/–</td>
</tr>
<tr>
<td>CD105</td>
<td>+</td>
<td>–/–</td>
</tr>
<tr>
<td>CD106</td>
<td>+</td>
<td>+/–</td>
</tr>
<tr>
<td>CD117</td>
<td>–/–</td>
<td>–</td>
</tr>
<tr>
<td>Stro-1</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Flik-1</td>
<td>+/-</td>
<td>–</td>
</tr>
<tr>
<td>Sca-1</td>
<td>–</td>
<td>+/–</td>
</tr>
</tbody>
</table>

CD, cluster of differentiation; FACS, fluorescence-activated cell sorter; Flik-1, vascular endothelial growth factor receptor 1; Stro-1, stromal antigen 1; Sca-1, stem cell antigen 1.
subject of investigation for the purpose of understanding the mechanisms(s) of immunomodulatory action afforded by MSCs. NK cells display natural cytolytic activity against the cells that are missing markers of self-major histocompatibility complex (MHC) class I. Although initially it was thought that MSCs could escape NK cell immunosurveillance, it was recently shown that NK cells can also efficiently lyse MSCs, despite the expression of high levels of HLA-I by MSCs (30,31). The NK receptors NKp30, NKG2D, and DNAM-1 were implicated in the process of NK-mediated cytotoxicity against MSCs. However, MSCs could suppress proliferation of NK cells, decrease the secretion of IFN-γ by IL-2–stimulated NK cells, and affect cytotoxicity against HLA class I–expressing targets. Combination effects of cell-to-cell contact and soluble factors, including transforming growth factor-β (TGF-β), heme oxygenase (HO)-1, prostaglandin (PG), or indolamine 2,3-dioxygenase (IDO) (5). MSCs may also act through downregulation of immunoglobulin production by B-cells (6). Finally, upregulation of MHC class II on MSCs could lead to downregulation of NK cell cytotoxicity and proliferation (7). DC, dendritic cells; HGF, hepatic growth factor; TGF, transforming growth factor; TNF, tumor necrosis factor.

One additional and crucial feature of MSCs is their ability to selectively migrate to sites of injury. Chemokines are increasingly being recognized as the key regulators of this preferential migration, and since MSCs express a variety of chemokine receptors and adhesion molecules (35), they are also likely to be of significance in vivo. Finally, interactions between MSCs and endothelial cells have been shown to be in part VLA-4/vascular cell adhesion molecule (VCAM) dependent (15).

**MSCs and their hypo-immunogenicity.** Because of the lack in expression of MHC class II and most of the classical costimulatory molecules on MSCs, these cells have historically been regarded as hypo-immunogenic cells (36). MSCs cultured with responder T-cells do not generally cause T-cell proliferation. However, recent studies suggest that MSCs are not as immunoprivileged as once thought (37).

MSCs do in fact have a large number of receptors that equip them to interact with T-cells. MHC class I and a variety of adhesion molecules, including cell adhesion molecule (CD106; VCAM), intercellular adhesion molecule 1 (ICAM-1), activated leukocyte cell adhesion molecule (CD11a; ALCAM), lymphocyte functional antigen-3 (CD58), and many other integrins on MSCs can find their counterpart ligands on T-cells (15). MHC class II is commonly reported to be absent on the surface of MSCs, but Western blotting on cell lysates has shown that the cells contain intracellular deposits of class II alloantigens (38,39). Furthermore, MSCs stimulated by IFN-γ exhibit induction of class II molecule expression (40). Because, in many inflammatory milieus, IFN-γ is upregulated, this may increase the expression of MHC class II. Although MSCs may not induce lymphocyte activation, at least as measured through proliferation, MSCs have been shown to alter cytokine production (39). Recent studies suggest that although transplanted allogeneic MSCs can be detected in recipients for extended periods, they are recognized by the host immune response and eventually get rejected (15).

**MSCs and their immunomodulatory properties in vivo.** Although regenerative capabilities of MSCs have been a driving force in initiating initial studies testing
Among early reports responsible for stirring this interest was a study by Bartholomew et al. (17) in which the investigators demonstrated that donor MSC administered intravenously to MHC-mismatched recipient baboons before placement of second- and third-party skin grafts led to prolonged allograft survival. Zappia et al. (43) have also studied the immunoregulatory ability of murine MSCs to treat myelin oligodendrocyte glycoprotein–induced experimental autoimmune encephalomyelitis in C57BL/6J mice. In that effort, MSCs were injected intravenously before disease onset (i.e., preventative protocol) as well as at different time points after disease occurrence (i.e., therapeutic protocol). MSC administration before disease onset strikingly ameliorated experimental autoimmune encephalomyelitis, and overall, the therapeutic scheme was effective when MSCs were administered at disease onset as well as at the peak of disease, but not during the chronic phase. The immunoregulatory properties of MSCs interfered effectively with the autoimmune attack in the course of experimental autoimmune encephalomyelitis, inducing an in vivo state of T-cell unresponsiveness within secondary lymphoid organs. Recently, Augello et al. (44) from our group demonstrated that allogeneic murine MSCs are able to prevent tissue damage in collagen-induced arthritis, a mouse model for human rheumatoid arthritis in DBA-1 mice, and showed that MSCs exert their immunomodulatory function by educating antigen-specific regulatory T-cells. MSCs have also been successfully used in the treatment of steroid-refractory graft versus host disease (GVHD) in both experimental animals (45) and in humans (46,47). Yaneez et al. (48) reported the successful control of their therapeutic effectiveness, the immunomodulatory properties of MSCs have recently become equally exciting for investigators in terms of examining their potential implications in a variety of disease models. MSCs have been tested in rodent animal models to treat diseases where immunomodulation is thought to be the main operative mechanism (Table 2). However, it is also important to note that even in the studies focusing on the plasticity of MSCs, the benefit effects observed could also have been due to the immunomodulatory capacities of MSCs (41,42).

Notably, the MSC literature is lacking in reports on the use of MSCs in animal models of diabetes. Lee et al. (59) used immunodeficient recipient mice (NOD,SCID), chemically rendered diabetic by streptozotocin injections, to study the effect of human MSCs (hMSCs) in the development of diabetes. Infusion of hMSCs reduced glycemic levels and increased peripheral insulin levels (59). Human DNA infused as hMSCs was detected in the pancreas as well as in the kidney (59).

In pancreata from hMSC-treated diabetic mice, the islets appeared larger compared with islets from untreated diabetic mice (59). Also, the islets had an increase in mouse insulin immunoreactivity. Few human cells were detected in islets of the hMSC-treated diabetic mice by labeling sections with antibodies to human-2-microglobulin and mouse insulin (59). Kidneys from untreated diabetic mice contained many abnormal glomeruli with increased deposits of extracellular matrix protein in the mesangium (59), whereas in hMSC-treated diabetic mice, glomeruli were normal (59).
<table>
<thead>
<tr>
<th>Condition/therapy</th>
<th>Site/sponsor</th>
<th>Status</th>
</tr>
</thead>
</table>
| **Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and GVHD**  
Hematological malignancies | BM-derived donor MSC  
University Hospital of Liege, Belgium | Recruiting |
| **Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS)**  
Multiple sclerosis | BM-derived autologous MSC  
University of Cambridge, U.K. | Not yet recruiting |
| **Prochymal Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-Severe Crohn's Disease**  
Crohn's disease | BM-derived allogeneic MSC (Prochymal)  
OsirisTherapeutics, U.S. | Active, not recruiting |
| **Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute GVHD or Poor Graft Function**  
GVHD | BM-derived allogeneic MSC  
University Hospital of Liege, Katholieke Universiteit Leuven, Belgium | Recruiting |
| **Evaluation of the Role of Mesenchymal Stem Cells in the Treatment of GVHD**  
GVHD | BM-derived donor MSC  
Christian Medical College, India | Recruiting |
| **Treatment of Refractory GVHD by the Infusion of Expanded In-Vitro Allogeneic Mesenchymal Stem Cell**  
GVHD | BM-derived allogeneic MSC  
University of Salamanca, Spain | Recruiting |
| **Extended Evaluation of PROCHYMAL Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease**  
Crohn's disease | BM-derived allogeneic MSC (Prochymal)  
Osiris Therapeutics, U.S. | Recruiting |
| **Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD**  
GVHD | BM-derived allogeneic MSC (Prochymal)  
Osiris Therapeutics, U.S. | Recruiting |
| **Follow-up Study to Evaluate the Safety of Prochymal for the Treatment of GVHD Patients**  
GVHD | BM-derived allogeneic MSC  
M.D. Anderson Cancer Center, TX  
Osiris Therapeutics, U.S. | Active, not recruiting |
| **Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Gastrointestinal Graft Versus Host Disease**  
GVHD | BM-derived allogeneic MSC (Prochymal)  
Osiris Therapeutics, U.S. | Completed |
| **Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic GVHD After Undergoing a Donor Stem Cell Transplant**  
GVHD | BM-derived donor MSC  
Case Comprehensive Cancer Center, L.S.  
National Cancer Institute (NCI)  
M.D. Anderson Cancer Center, TX  
Osiris Therapeutics, U.S. | Recruiting |
| **Evaluation of PROCHYMAL Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease**  
Crohn's disease | BM-derived allogeneic MSC (Prochymal™)  
Osiris Therapeutics, U.S. | Recruiting |
| **Prochymal Infusion for the Treatment of Steroid-Refractory Acute GVHD**  
GVHD | BM-derived allogeneic MSC (Prochymal)  
M.D. Anderson Cancer Center, TX  
Osiris Therapeutics, U.S. | Recruiting |
| **Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD Patients**  
GVHD | BM-derived allogeneic MSC (Prochymal)  
Osiris Therapeutics, U.S. | Completed |
| **OTI-010 for Graft-Versus-Host Disease (GvHD) Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematological Malignancies**  
Hematological malignancies | BM-derived autologous MSC  
Johnson Comprehensive Cancer Center, USA  
National Cancer Institute (NCI) | Active, not recruiting |
| **Efficacy and Safety of Prochymal Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute GVHD**  
GVHD | BM-derived allogeneic MSC (Prochymal)  
Osiris Therapeutics, U.S. | Recruiting |

BM, bone marrow; Prochymal, allogeneic human MSC produced by Osiris Therapeutics.
GVHD in mice but with extraction of murine MSCs from a different cellular source (i.e., adipose tissue).

While the aforementioned studies certainly provide support for the therapeutic utility of MSCs, it should also be noted there has been contradictory data using MSCs as well. Sudres et al. (49) reported that murine MSCs were unable to ameliorate the outcome of a GVHD reaction in mice. Nauta et al. (37) examined the role of recipient and donor MSC in sublethally irradiated recipients receiving allogeneic bone marrow. Whereas the host MSCs significantly enhanced the long-term engraftment associated with tolerance to host and donor antigens, the infusion of donor MSCs significantly increased rejection of allogeneic bone marrow cells. In heart transplant models in rats, Inoue et al. (50) have shown that MSC injection not only failed to prolong allograft survival, but when MSCs were co-administered with low-dose cyclosporine, it accelerated allograft rejection.

**Clinical trials using MSCs in humans.** MSCs were first shown to accelerate the recovery in a patient with a severe case of GVHD (46). A limited but growing number of follow-up studies involving MSCs have been reported since, most aimed at taking advantage of the plasticity of MSCs to treat a disease. These clinical studies (Table 3) have demonstrated promising results in treating patients with cancer, in reducing the incidence of GVHD after bone marrow transplantation, in promoting heart tissue recovery from massive myocardial infarction, in improving the recovery of patients after amyotrophic lateral sclerosis, and in treating fatal disorders such as metachromatic leukodystrophy and Hurler syndrome (47,51–53). At the time of this Perspectives in Diabetes article’s submission, ~32 clinical trials involving administration of MSCs were listed at http://www.ClinicalTrials.gov, each potentially seeking to exploit the immunomodulatory properties of MSCs to achieve their desired therapeutic goal. In terms of type 1 diabetes, the Juvenile Diabetes Research Foundation recently announced its intent to fund the commercial entity Osiris to evaluate the immunomodulatory effects of Prochymal, a formulation of immunomodulatory adult bone marrow–derived MSCs, for the purpose of improving disease management in individuals with type 1 diabetes.

**FUTURE CHALLENGES FOR MSC TRIALS**

While MSC-based cell therapy is clearly promising and has been used in multiple disease scenarios with no unforeseen events (at least to date), whether any long-term complications arise from this strategy remains uncertain. As a result, many of the clinical trials are placing a high emphasis on addressing issues related to the safety of MSCs. Thus, MSC-based cell therapy still faces many hurdles, in particular addressing the safety issues, before widespread clinical applicability becomes feasible. In addition to the general challenges any cell-based therapy face, there are additional issues specific to MSCs (Table 4), especially in the context of type 1 diabetes.

**Standardization and quality-control studies of MSCs.** Similar to stem cells, MSC characteristics and phenotype vary according to the passage cycle, culture conditions, and source of the MSCs (e.g., bone marrow, blood, cord blood, etc.). This could explain the differential outcome data that have been noted by investigators using their particular model of interest. Thus, there is a strong need to define these conditions as the field of MSC-based therapies moves forward.

In particular, a major safety issue of note is the need for fetal calf serum (FCS) to maintain MSC culture. Because FCS has been associated with transmission of diseases or undesirable immune responses to it, studies to develop and measure the safety of FCS-free culture medium are necessary. Furthermore, there is a need to define a dose range for cells and protocol of administration that result in optimal efficacy. This is particularly relevant to type 1 diabetes where, as will be discussed below, a potential exists to identify patients at increased risk for the disease and thereby allow for the development of prevention strategies; this is in addition to therapeutic protocols seeking to reverse the disorder in patients shortly after disease onset. Finally, development of refined immunologic and molecular assays capable of monitoring therapeutic efficacy must go hand in hand with planning of initial trials to make this form of therapy widely available for clinical application.

**Potential tumorigenicity of MSCs.** Although malignant transformation of MSCs has not been noted to date in the clinical trials using human MSCs, expansion in vitro for extended periods of time can confer risk of chromosomal instability and malignant transformation (54). It is also possible that the tendency for MSCs to undergo malignant transformation could vary according to the species (i.e., human vs. mice), source (i.e., adipose tissue vs. bone marrow), preparation, and cell cycle at the time of use. Therefore, MSCs maintained in a prolonged culture may not be risk free. Therefore, a greater understanding of MSC biology is needed to establish safe criteria for their use.

**Differentiation of MSCs to unwanted tissues.** The potential for MSCs to differentiate into other mesenchymal lineages (e.g., bone) could also be problematic, as was observed in the case calling for replacement of cardiac tissues (55). As noted, transformation of transplanted bone marrow material into mesodermal tissues has long been recognized (2). This is clearly an issue when MSCs are locally administered. Efforts are taken to prevent this unwanted transdifferentiation by in vivo and ex vivo stimulation of MSCs with a variety of factors (56). In the
case of systemic administration of MSC for treating autoimmunity, it is interesting to examine the value of manipulating MSCs before administration to enhance their immunomodulatory function, which could be tested in the appropriate in vitro assays. It is of value to test the idea of directing MSCs to specific lymphoid tissues where they could exert their immunomodulatory function locally where all actions take place. Therefore, there is a need for better understanding of the roles of factors that could determine their fate post-delivery.

MSCs FOR THE TREATMENT OF TYPE 1 DIABETES

Why MSCs? Despite the efforts of many, the frequency of type 1 diabetes has been steadily increasing worldwide. When taken together with the costs (both fiscal and physical) associated with the treatment of its complications, a setting has been formed where research on this disease has become priority for the field of autoimmunity. Here, the challenge involves the development of safe and effective means affording the prevention or reversal of type 1 diabetes. This would represent a remarkable accomplishment, especially when one considers that type 1 diabetes prevention studies using immunosuppressants, self-antigens, and dietary interventions (among others) have thus far demonstrated largely disappointing results (57). Indeed, even if efforts involving the aforementioned immunosuppressive agents were, over time, proven effective, the high morbidity associated with lifelong immunosuppression would remain a major limitation. As such, we and others have sought to search for other preventative measures, including MSCs. The logical question and close for this article would be to address the practical issue (with respect to MSC therapy) of why one would consider MSCs as an immune intervention for type 1 diabetes.

First, the immunological properties associated with MSCs would appear to target facets thought pathogenic for type 1 diabetes. In NOD mice, it appears that several defects in maintaining peripheral and central tolerance lead to development of autoimmune diabetes. A combination of immune cell dysfunction (including T-cell, NK cells, B-cells, and dendritic cells), as well as the presence of inflammatory cytokine milieu in a coordinated fashion, leads to this failure to maintain tolerance to β-cells (58). Furthermore, as detailed earlier in this article, MSCs possess specific immunomodulatory properties that (based on our collective knowledge of the pathogenic factors that lead to β-cell destruction in type 1 diabetes) would appear capable of disabling autoimmunity through immunomodulation. One could speculate that MSCs could regulate diabetes through a direct effect by presenting differential levels of negative costimulatory molecules and secreting regulatory cytokines such as transforming growth factor-β and IL-10 that control regulatory T-cells/autoreactive T-cells. It is also possible that MSCs could correct the dysregulation observed at the level of B-cells and NK cells as well. Dendritic cells have been shown to be defective in NOD mice having a higher level of costimulation and having capability to shift to a Th1 type of immune response. Given the data showing interaction of MSCs with dendritic cells resulting in formation of regulatory dendritic cells, we also propose that MSCs could regulate type 1 diabetes through an indirect effect by regulating dendritic cell function. MSCs also exert anti-inflammatory effects that could be important in maintaining peripheral tolerance. Beyond this, there is the important issue of safety. While type 1 diabetes can develop in individuals at any age, it remains a disease wherein a majority of subjects are children and adolescents, individuals for whom safe interventions should be given primary consideration. This notion would be even more important were this form of therapeutic intervention applied to disease prevention in individuals considered at increased risk for type 1 diabetes (i.e., those with genetic susceptibility, autoantibodies). Finally, as discussed previously, MSCs have shown promising results in the treatment of other autoimmune disorders (e.g., experimental autoimmune encephalomyelitis and rheumatoid arthritis).

In summary, although the immunomodulatory effects of MSCs make them particularly interesting candidates for the treatment of this disease, future studies should evaluate the effect of MSCs on the prevention of and cure for type 1 diabetes through their immunomodulatory effects by examining mechanistic bases for this phenomenon first in mice and then in pilot human studies (Table 5). However, to date, the role of MSCs in type 1 diabetes remains completely unexplored. We are optimistic that future efforts in this area will shed light on the functions of MSCs as immunomodulators of the autoimmune response, providing a proof of principle to translate to clinical trials in humans.

| Source of MSC | To elucidate the differential immunomodulatory properties of bone marrow, blood, and cord blood MSC |
| Documentation of MSC engraftment | To study the life span of MSC after systemic administration |
| Homing of MSC to appropriate environment | To anatomically localize MSC in lymphoid tissues and pancreas and determine their potential differentiation into islets |
| Autologous vs. allogeneic MSC | To study differential anti-diabetes influence of MSC from NOD, NOR and allogeneic MSC |
| MSC passage, cell infusion number, frequency, duration, concurrent immunosuppression, and pre-injection manipulation of MSC | To optimize the therapy |
| Monitoring of a therapeutic response | To develop specific in vitro assays to measure MSC anti-autoimmune properties |

### Table 5

Recommended studies to address the potential implications of MSC therapy for type 1 diabetes
MESENCHYMAL STEM CELLS AND TYPE 1 DIABETES

ACKNOWLEDGMENTS

This work was supported by the Juvenile Diabetes Research Foundation grants 17-2008-365 (to M.H.S.) and 7-2006-328 (to M.A. and M.H.S.).

We thank Professor Samia J. Khoury for helpful review and suggestions.

REFERENCES

7. Caplan AI: Mesenchymal stem cells. 2:75–81, 2007
18. Ryan JN, Barry FP, Murphy JM, Mahon BP: Mesenchymal stem cells avoid allogeneic rejection. J Immunol (Lond) 2:5, 2005


